文献速递艾滋病与性传播感染

HIV感染者从整合酶链转移抑制剂转换为多拉韦林再换回后的能量平衡与体成分

Energy balance and body composition after switch between integrase strand transfer inhibitors and doravirine among people with HIV.
PubMed 文献 · J Antimicrob Chemother · 2024-01-01

研究纳入18例在含整合酶链转移抑制剂(INSTI)方案上体重增加>10%的HIV感染者,先将INSTI转换为多拉韦林12周,再换回INSTI 12周。转换为多拉韦林后24小时能量消耗呈下降趋势,体重、躯干脂肪和无脂体重均呈轻度下降趋势,但变化均未达统计学显著。

要点

  • 在INSTI方案上体重增加>10%的HIV感染者转换为多拉韦林后,24小时能量消耗呈下降趋势。
  • 转换为多拉韦林后体重、躯干脂肪和无脂体重均呈下降趋势,换回INSTI后部分指标略有回升。
  • 上述变化均未达统计学显著,作者认为提示多拉韦林可能具有轻度抑制体重的作用。

核心结论

  • 在INSTI方案上体重增加>10%的HIV感染者中,转换为多拉韦林与24小时能量消耗、体重、躯干脂肪量和无脂体重下降的趋势相关。
  • 观察到的变化均未达统计学显著,但提示多拉韦林在HIV感染者中可能具有轻度抑制体重的作用。

研究设计与样本

  • 研究为自身前后对照设计:HIV感染者在含INSTI方案上体重增加>10%后,将INSTI转换为多拉韦林12周,再换回INSTI 12周,其余方案保持不变。
  • 共纳入18例参与者,在INSTI治疗时、转换为多拉韦林后及重新启动INSTI后分别测量24小时能量消耗、能量摄入和体重,采用混合模型分析随时间的变化。

主要发现

  • 转换为多拉韦林后,未校正的24小时能量消耗下降83 kcal(95% CI -181至14),重新启动INSTI后下降2 kcal(95% CI -105至100)。
  • 能量平衡(能量消耗减能量摄入)从第0周到第12周增加266 kcal(95% CI -126至658),从第12周到第24周下降3 kcal(95% CI -429至423)。
  • 转换为多拉韦林后体重呈下降趋势,平均-1.25 kg(95% CI -3.18至0.69);换回INSTI后平均-0.47 kg(95% CI -2.45至1.52)。
  • 多拉韦林治疗期间躯干脂肪减少474 g(95% CI -1398至449),重新启动INSTI后部分回升199 g(95% CI -747至1145)。
  • 多拉韦林治疗期间无脂体重减少491 g(95% CI -1399至417),重新启动INSTI后略有增加178 g(95% CI -753至1108)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Integrase strand transfer inhibitors (INSTIs) are associated with excessive weight gain among a subset of persons with HIV (PWH), due to unclear mechanisms. We assessed energy intake (EI) and expenditure (EE) following switch off and onto INSTIs. METHODS: PWH with >10% weight gain on an INSTI-based regimen switched INSTI to doravirine for 12 weeks, then back to INSTI for 12 weeks while keeping their remaining regimen stable. Twenty-four-hour EE, EI and weight were measured on INSTI, following switch to doravirine, and upon INSTI restart. Mixed models analysed changes over time. RESULTS: Among 18 participants, unadjusted 24 h EE decreased by 83 (95% CI -181 to 14) kcal following switch to doravirine, and by 2 (-105 to 100) kcal after INSTI restart; energy balance (EE-EI) increased by 266 (-126 to 658) kcal from Week 0 to Week 12, and decreased by 3 (-429 to 423) kcal from Week 12 to Week 24. Trends toward weight loss occurred following switch to doravirine [mean -1.25 (-3.18 to 0.69) kg] and when back on INSTI [-0.47 (-2.45 to 1.52) kg]. Trunk fat decreased on doravirine [-474 (-1398 to 449) g], with some regain following INSTI restart [199 (-747 to 1145) g]. Fat-free mass decreased on doravirine [-491 (-1399 to 417) g] and increased slightly after INSTI restart [178 (-753 to 1108) g]. CONCLUSIONS: Among PWH with >10% weight gain on an INSTI, switch to doravirine was associated with a trend towards decreases in 24 h EE, weight, trunk fat mass and fat-free mass. Observed changes were not significant, but suggest a mild weight-suppressive effect of doravirine among PWH.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Erlandson KM, Mohaweche R, Morrow M, et al. Energy balance and body composition after switch between integrase strand transfer inhibitors and doravirine among people with HIV. J Antimicrob Chemother. 2024. PMID: 38000089. doi:10.1093/jac/dkad363

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。